Pediatrix Medical Group, Inc.

Hello and thank you for standing by. At this time, I would like to welcome everyone to the Q1 2026 Pediatrics Medical Group Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, just press star followed by the number one on your telephone keypad. And if you would like to withdraw your question, press star one again. Thank you. I would now like to turn the conference over to Marianne Moore, General Counsel. You may begin.

Thank you operator and good morning. Certain statements and information during this conference call may be deemed to be forward looking statements within the meeting of the Federal Private Securities Litigation Reform Act of 1995. These forward looking statements are based on assumptions and assessments made by pediatrics management in light of their experience and assessment of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Any forward looking statements made during this call are made as of today. and Pediatrics undertakes no duty to update or revise any such statements, whether as a result of new information, future events, or otherwise. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the company's filings with the SEC, including the sections entitled Risk Factors. In today's remarks by management, we will be discussing non-GAAP financial metrics, a reconciliation of these non-GAAP financial measures, to the most comparable gap measures can be found in this morning's press release, our quarterly and annual reports, and on our website at www.pediatrics.com. With that, I will turn the call over to Mark Hordan, our Chief Executive Officer.

Thank you, Mary Ann, and good morning, everyone. Also with me today is Cassandra Rossi, our Chief Financial Officer. We were pleased with our strong first quarter results, driven by top-line growth with adjusted EBITDA coming in at $58 million. We saw strong pricing that outpaced a modest decline in same-unit volumes across our service lines, although recent volume results don't show a trend. Our paramic continues to be strong, and we are comfortable with our decision to not have a headwind estimate for the potential effect of the tax subsidy lapse. We know that major hospital systems have seen a decline in patient volume and revenue, and we may see that in the future. So now this area is strongly and we will continue to report on it as the year continues. Given the uncertainty of whether we will experience this headwind, and since it's still early in the year, we are reaffirming our full 2026 outlook of $280 to $300 million in adjusted EBITDA. Cassandra will now provide some additional details, and I'll be back shortly.